Bluebird Bio

This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal. The US biotech could receive $70m in development milestones for the candidate. ... Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy

Latest news

Celgene reaches $9bn agreement to buy Juno

rival to Bluebird Bio’s BB2121, which Celgene licenses.
Gilead adds to CAR-T assets with Cell Design Labs buyout

from Bluebird Bio were highlighted.
CAR-T therapies show long-term benefits in lymphoma

There was also good news from another earlier trial of a BCMA-targeting CAR-T bb2121 being developed by Celgene and Bluebird Bio, which showed the candidate was able to achieve
Gilead makes $11.9bn play for CAR-T specialist Kite

Other CAR-T players, like Juno and Bluebird Bio, are a little further back in development.
Novartis buys blood disease specialist Selexys

Meanwhile, down the line patients could see potential gene therapy treatments start to appear from the likes of Biogen/Sangamo and Bluebird Bio.

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and
Pharma deals in May 2015

Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell
Deal Watch table for June 2014

208. Pregenen/ bluebird bio. Company acquisition. Gene editing technology platform. 156.
Pharma deals during March 2013

344. Bluebird bio/ Celgene Corporation. Option &licence. CAR T-cell therapy for oncology (platform).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Celgene boosts CAR-T stake again with Bluebird Bio deal

Celgene boosts CAR-T stake again with Bluebird Bio deal. The US biotech could receive $70m in development milestones for the candidate. ... Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy
Proteostasis Therapeutics strengthens leadership team

James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager – Med Comms – Kent: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Project Manager, Medical Communications, London: Excellent Salary

Senior Medical Writer: Great salary and benefits

Senior Account Manager / Account Director: Great salary and bebefits

Scientific Director: Great salary and bebefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager or AD - Medical Communications: Salary TBC

Project Manager, Medical Communications, Oxford: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Editor – Medical Education Agency – Bucks: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Programme Executive: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Medical Writer - (London, Brighton or Copenhagen): Competitive

Medical Writer, e-learning/ training, London: Excellent Salary

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation: HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...